Selected Articles from This Issue

Highlights| April 01 2024 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2024 American Association for Cancer Research2024American Association for Cancer Research Clin Cancer Res (2024) 30 (7): 1215. https://doi.org/10.1158/1078-0432.CCR-30-7-HI Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record April 1 2024 Citation Selected Articles from This Issue. Clin Cancer Res 1 April 2024; 30 (7): 1215. https://doi.org/10.1158/1078-0432.CCR-30-7-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Platinum-based chemotherapy maintenance regimens are often limited by toxicities, highlighting a need for chemotherapy-free strategies that retain efficacy. Previous studies have demonstrated the success of PARP inhibitors (PARPi) in maintenance therapy, even in patients negative for germline BRCA mutations. Additional work illustrating a PARPi-mediated upregulation of immune checkpoint molecules and enhanced immune response suggests a potential for synergism between PARPi and immune checkpoint inhibitors (ICI). In the phase II DORA study, Tan and colleagues investigate the use of the PARPi olaparib with or without the PD-L1-targeted ICI durvalumab in patients with advanced triple negative breast cancer previously treated with platinum-based chemotherapy. Treatments were tolerable, and the authors report a median progression-free survival of 4.0 months with olaparib and 6.1 months with olaparib plus durvalumab, both significantly longer than previously observed outcomes. Germline BRCA mutation or PD-L1 status had no observable effect on clinical benefit, yet patients who had achieved partial... You do not currently have access to this content.